Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health Companies Inc. (NYSE/TSX: BHC) has appointed Tom Vadaketh as Chief Financial Officer (CFO) of Bausch Pharma, effective January 3, 2022. Sam Eldessouky will transition to CFO of Bausch + Lomb following its IPO completion. Vadaketh brings over 30 years of financial experience from various roles, including CFO positions at reputable firms. This leadership change aims to strengthen Bausch Pharma's financial management as they prepare for the IPO of their eye health business. The company emphasizes its commitment to advancing global health through innovative products.

Bausch Health Companies (NYSE/TSX: BHC) announced the presentation of eight posters at the Fall Clinical Dermatology Conference from Oct. 21-24, 2021. These posters will showcase analyses of the efficacy and safety of ARAZLO^® (tazarotene) Lotion, DUOBRII^® (halobetasol propionate and tazarotene) Lotion, and SILIQ^® (brodalumab) injection. The presentations include key findings on long-term outcomes, quality of life improvements, and treatment recommendations for onychomycosis. Two educational events focusing on ARAZLO and DUOBRII will also be held during the conference.

Bausch + Lomb announced positive outcomes from the one-year evaluation of its LuxSmart™ lens, designed for continuous vision from distance to intermediate. Since its 2020 European launch, 5,000 cataract patients have been treated with the lens, adopted by 200 surgeons across 18 countries. Evaluation results indicate excellent vision performance with minimal dysphotopsia. The lens is preloaded and suitable for patients with co-morbidities, with up to 30% of patients gaining near vision.

There is a growing global market for presbyopia solutions, with an expected 1.8 billion people affected by 2050.

Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its third-quarter 2021 financial results on November 2, 2021, at 8:00 a.m. ET. The event will include a conference call for discussion on the results and a business update, accessible via the company's Investor Relations site. The company specializes in pharmaceutical, medical devices, and over-the-counter products focusing on eye health, gastroenterology, and dermatology.

Bausch Health and Novaliq announced statistically significant topline results from the MOJAVE Phase 3 trial of NOV03, a novel eye drop treatment for dry eye disease associated with Meibomian gland dysfunction. The trial met primary endpoints, showing significant improvements in total corneal staining and dryness scores at day 57, p < 0.001. These findings reaffirm the safety and efficacy observed in earlier trials. A New Drug Application to the FDA is anticipated in 2022, potentially marking a significant advancement in treating millions suffering from dry eye disease.

Bausch Health Companies released its annual Environmental, Social and Governance (ESG) Report on Sept. 29, 2021, emphasizing a commitment to sustainability and stakeholder engagement. The report outlines progress in five key areas: Operate with Integrity, Respect the Environment, Advance Global Health, Improve Communities, and Support Employee Growth. Highlights include enhancing Diversity, Equity & Inclusion initiatives, expanding recycling efforts, and product donations during COVID-19. The full report is available on Bausch Health's website.

Bausch Health announced that new Health Economic Outcomes Research (HEOR) data on RELISTOR will be shared at PAINWeek 2021 in Las Vegas from Sept. 7-11, 2021. The research highlights the use of RELISTOR in treating opioid-induced constipation (OIC) in emergency department patients. Three abstracts will be presented, showcasing broad utilization across care settings. RELISTOR, an opioid antagonist, is indicated for OIC in adults, including those with chronic non-cancer pain and advanced illness.

Bausch Health Companies (NYSE/TSX: BHC) announced participation in several upcoming investor conferences. Executives, including Sam Eldessouky and Joseph C. Papa, will represent the company at the J.P. Morgan European High Yield & Leveraged Finance Conference on Sept. 9, 2021, and the Deutsche Bank 29th Annual Leveraged Finance Conference on Oct. 4, 2021. The Morgan Stanley Global Healthcare Conference is scheduled for Sept. 13, 2021. Live webcasts will be accessible on the company's Investor Relations page.

Bausch Health Companies Inc. (NYSE/TSX: BHC) reported second-quarter 2021 revenues of $2.100 billion, a 26% increase year-over-year. However, the company faced a GAAP net loss of $595 million, worsening from $326 million in Q2 2020. Adjusted EBITDA reached $826 million, up 33%. The company announced plans for an IPO of Solta Medical and appointed Thomas J. Appio as CEO of Bausch Pharma. Guidance for 2021 revenue was revised to $8.40 - $8.60 billion, reflecting divestitures and quality issues.